UPDATE - Barclays Downgraded Gilead Sciences (GILD) to Equalweight; Now One of Several Players
GILD Hot Sheet
Rating Summary:12 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 24 | Down: 11 | New: 36
UPDATE - Barclays downgraded Gilead Sciences (NASDAQ: GILD) from Overweight to Equalweight, price target lowered froM $67 to $53.
Analyst, C. Anthony Butler, said, "We downgrade GILD for the following reasons: 1) we think GILD is more likely to become one of several players in the HCV space, as opposed to the majority leader assumed by consensus; 2) with lower peak HCV sales, GILD's long-term (FY11-20E) revenue/EPS CAGR is in the middle of the range as compared to peers; and 3) we see limited near-term upside momentum going into CROI/EASL and further AASLD."
Butler sees peak sales of GS-7977 of approx. $3.8 bln (equal to 30% of the total oral HCV market) compared to the consensus of 50% or more.
Shares opened lower and have continued to sink...currently trading at $45.27, down $1.73 (-3.68%).
To see more ratings on GILD, Click Here
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, C. Anthony Butler, said, "We downgrade GILD for the following reasons: 1) we think GILD is more likely to become one of several players in the HCV space, as opposed to the majority leader assumed by consensus; 2) with lower peak HCV sales, GILD's long-term (FY11-20E) revenue/EPS CAGR is in the middle of the range as compared to peers; and 3) we see limited near-term upside momentum going into CROI/EASL and further AASLD."
Butler sees peak sales of GS-7977 of approx. $3.8 bln (equal to 30% of the total oral HCV market) compared to the consensus of 50% or more.
Shares opened lower and have continued to sink...currently trading at $45.27, down $1.73 (-3.68%).
To see more ratings on GILD, Click Here
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Canaccord Genuity Reiterates a 'Buy' on InterMune Inc. (ITMN); Reducing Estimates and PT
- Nomura Securities Maintains a 'Buy' on Melco Crown Entertainment (MPEL); Raising PT and Estimates
- Needham & Company Reiterates a 'Buy' on NetApp (NTAP); Solid 4Q Overshadowed by Conservative 1Q
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
